Sudeep Pharma Makes Stock Market Debut with Strong Investor Backing
The Indian pharmaceutical sector witnesses a significant addition today as Sudeep Pharma Limited makes its much-anticipated entry into the stock market. The company's equity shares will commence trading on both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) starting from 10:00 AM on Friday, November 28, 2025.
Robust Subscription Numbers Fuel Optimism
The initial public offering that paved way for today's listing demonstrated exceptional investor confidence, being subscribed 93.72 times overall. Breaking down the subscription data reveals even more impressive figures across investor categories. The Qualified Institutional Buyers (QIBs) segment led the charge with a massive 213.08 times subscription, while Non-Institutional Investors (NIIs) showed strong interest with 116.72 times booking. Retail Individual Investors participated actively with the category being subscribed 15.65 times.
The bidding process for this pharmaceutical ingredients manufacturer ran from November 21 to November 25, 2025, with the allotment finalization completed on November 26, 2025. The company successfully raised ₹895 crore through this public issue, structured as a combination of fresh issue worth ₹95 crore and an offer-for-sale component amounting to ₹800 crore.
Grey Market Signals Strong Debut Performance
Ahead of the formal listing, the grey market premium (GMP) for Sudeep Pharma shares has surged to ₹121 per share, indicating strong secondary market demand. This substantial premium suggests that the estimated listing price could reach approximately ₹714 per share, representing a more than 20% premium to the upper end of the IPO price band of ₹593 per share.
The stock exchange notification clearly stated: "Trading Members of the Exchange are hereby informed that effective from Friday, November 28, 2025, the equity shares of Sudeep Pharma Limited shall be listed and admitted to dealings on the Exchange in the list of 'B' Group of Securities."
Market analysts attribute this positive sentiment to the company's strong positioning in the pharmaceutical ingredients sector and the overwhelming response from institutional investors. The Special Pre-open Session (SPOS) conducted today will help determine the equilibrium price before regular trading begins.
IPO Structure and Key Participants
The public offering featured a price band of ₹563 to ₹593 per share, with the company offering 1.35 crore shares through the offer-for-sale route and issuing 16.02 lakh fresh shares. The issue management was handled by ICICI Securities as the book running lead manager, while MUFG Intime India served as the registrar for the IPO process.
The successful listing of Sudeep Pharma adds another significant player to India's growing pharmaceutical manufacturing landscape and reflects continued investor appetite for quality offerings in the healthcare sector.
